These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22173961)

  • 21. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
    Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multinational observational study on clinical practices and therapeutic management of mineral and bone disorders in patients with chronic kidney disease stages 4, 5, and 5D: The OCEANOS study.
    Shaheen FA; Kurpad R; Al-Sayyari AA; Souqiyyeh MZ; Aljubori H; El Baz T; Kashif W; Tuganbekova S; Kabulbayev K; Jarraya F; Nafar M
    Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):290-304. PubMed ID: 26997382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults.
    Bellorin-Font E; Ambrosoni P; Carlini RG; Carvalho AB; Correa-Rotter R; Cueto-Manzano A; Jara A; Jorgetti V; Negri AL; Olaizola I; Salusky I; Slatopolsky E; Weisinger JR; ;
    Nefrologia; 2013; 33 Suppl 1():1-28. PubMed ID: 23629678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compliance with mineral metabolism targets in haemodialysis patients: moving backwards?
    Palomares I; Ramos R; Martin-Malo A; Merello JI; Praga M; Luño J; de Francisco AL;
    Blood Purif; 2013; 36(2):122-31. PubMed ID: 24217176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
    Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence to Kidney Disease: Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters.
    Roetker NS; Peng Y; Ashfaq A; Gilbertson DT; Wetmore JB
    Am J Nephrol; 2019; 49(3):225-232. PubMed ID: 30820015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends of elevated parathormone serum titers in hemodialysis patients on intensive therapy for bone disease: a multicenter study.
    Karkar A; Sinha AK; Abdelrahman M; Mushtaque F; Awn NM; Qadi Y; Nassar M; Algareeb A; Taha MI; Abdulkader M; Sabry A; Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2014 Nov; 25(6):1166-77. PubMed ID: 25394432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and management of mineral and bone disorders in infants with CKD: clinical practice points from the ESPN CKD-MBD and Dialysis working groups and the Pediatric Renal Nutrition Taskforce.
    Bacchetta J; Schmitt CP; Bakkaloglu SA; Cleghorn S; Leifheit-Nestler M; Prytula A; Ranchin B; Schön A; Stabouli S; Van de Walle J; Vidal E; Haffner D; Shroff R
    Pediatr Nephrol; 2023 Sep; 38(9):3163-3181. PubMed ID: 36786859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.
    Raji YR; Ajayi SO; Adeoye AM; Amodu O; Tayo BO; Salako BL
    Afr Health Sci; 2022 Mar; 22(1):344-351. PubMed ID: 36032486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
    Iwashita Y; Iwashita Y; Ito T; Shigematsu T
    Clin Calcium; 2016 Feb; 26(2):259-67. PubMed ID: 26813506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).
    Manns BJ; Hodsman A; Zimmerman DL; Mendelssohn DC; Soroka SD; Chan C; Jindal K; Klarenbach S
    Am J Kidney Dis; 2010 May; 55(5):800-12. PubMed ID: 20438984
    [No Abstract]   [Full Text] [Related]  

  • 34. Adaptation and implementation of the "Kidney Disease: Improving Global Outcomes (KDIGO)" guidelines for evaluation and management of mineral and bone disorders in chronic kidney disease for practice in the Middle East countries.
    Al Rukhaimi M; Al Sahow A; Boobes Y; Goldsmith D; Khabouth J; El Baz T; Mahmoud H; Ganji MR; Shaheen FA;
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):133-48. PubMed ID: 24434398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes.
    Chuang SH; Wong HC; Vathsala A; Lee E; How PP
    Singapore Med J; 2016 Nov; 57(11):603-609. PubMed ID: 26778726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mineral and bone disorder in chronic kidney disease : Critical appraisal of pharmacotherapy].
    Brunkhorst R
    Internist (Berl); 2014 Mar; 55(3):334-9. PubMed ID: 24522558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mineral and bone disorders in chronic kidney disease: new insights into mechanism and management.
    Lewis R
    Ann Clin Biochem; 2012 Sep; 49(Pt 5):432-40. PubMed ID: 22807503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.
    Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW
    Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council: Initial findings from the dialysis outcomes and practice patterns study (2012-2015).
    Al Salmi I; AlRukhaimi M; AlSahow A; Shaheen FA; Al-Ghamdi SM; AlAli F; AlGhareeb S; Al Maimani Y; AlGhonaim M; Bieber B; Tentori F; Pisoni RL;
    Saudi J Kidney Dis Transpl; 2016 Nov; 27(6 Suppl 1):62-80. PubMed ID: 27991480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short- and long-term impact of subtotal parathyroidectomy on the achievement of bone and mineral parameters recommended by clinical practice guidelines in dialysis patients: a 12-year single-center experience.
    Tsai WC; Peng YS; Yang JY; Hsu SP; Wu HY; Pai MF; Chang JF; Chen HY
    Blood Purif; 2013; 36(2):116-21. PubMed ID: 24217122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.